Clinical trials: Metastatic Colorectal Neoplasms
Phase 1, SAR445877
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
- Conditions
- Phase 1, SAR445877, FOlfox6, Bevacizimab
- Trial name
- NCT07500298
- Testing
- SAR445877, FOLFOX6, Bevacizumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
This phase Ib trial studies the best way of TLR8 Agonist VTX-2337 and cyclophosphamide in treating patients with a solid tumor that has spread from the primary site (place where it started) to other places in the body…
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT02650635
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Urinary Retention, Rectal Cancer
Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)
The objective of this trial is to investigate the effect of bladder training on the incidence of re-catheterization after proctectomy.
- Conditions
- Urinary Retention, Rectal Cancer, Urinary Catheterization
- Trial name
- NCT06217016
- Testing
- ICCAUT, Free drainage
- Where
- China
- Sponsor
- The First Hospital of Jilin University
Metastatic Colorectal Cancer
Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer
Description of active nutritional support: Early and active nutritional support is mainly concerned with maintaining protein and energy intake levels despite chemotherapy.
- Trial name
- CHIMIODIET (NCT01143285)
- Testing
- Early and active nutritional support.
- Where
- 8 sites in France
- Volunteers
- 180 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at the time of day that allows for the best drug response may allow the doctor to give higher…
- Trial name
- NCT00039208
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- 20 sites in Belgium, France and 2 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Colorectal Cancer
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
This is a prospective, open, multicenter, randomized controlled phase II study designed to observe the difference of efficacy, adverse events and quality of life between second-line and third-line application of Fruquintinib in…
- Trial name
- NCT05447715
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Weijian Guo
Colorectal Cancer
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.
- Trial name
- NCT03792568
- Testing
- ALK Inhibitor
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Metastatic Colorectal Cancer
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.
- Trial name
- MACBETH (NCT02295930)
- Testing
- folfoxiri+cetuximab+surgery+cetuximab, folfoxiri+cetuximab+surgery+bevacizumab
- Where
- 22 sites in Italy
- Volunteers
- 143 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with cetuximab; and then to evaluate the tumor response to BMS-908662 when administered alone or in combination with cetuximab
- Trial name
- NCT01086267
- Testing
- BMS-908662, Cetuximab
- Where
- 3 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Colorectal Cancer Metastatic
Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis
Colorectal cancer (CRC) has the third highest cancer incidence in the world. There is mounting evidence that the intestinal microbiota plays an important role in colorectal carcinogenesis.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Intestinal Parasite, Protozoan Infections
- Trial name
- NCT03173001
- Testing
- Parasitological examination
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Colorectal Cancer, Steatohepatitis
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
This multicenter randomized, placebo-controlled phase II study will enroll 132 first-line palliative treated subjects with metastatic KRAS wild type CRC.
- Trial name
- G-LUCAS (NCT01523639)
- Where
- 7 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Colorectal Cancer
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00544011
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Hopital Jean Minjoz
Progression Free Survival
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
Treatment options for patients with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case.
- Trial name
- TT (NCT01453257)
- Testing
- Tailored Chemotherapy
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Grupo Hospital de Madrid
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Prostatic Neoplasms, Esophageal Neoplasms
Tumor Hypoxia With HX4 PET in Several Diseases
Regulation of tissue oxygen homeostasis is critical for cell function, proliferation and survival. Evidence for this continues to accumulate along with our understanding of the complex oxygen-sensing pathways present within…
- Conditions
- Prostatic Neoplasms, Esophageal Neoplasms, Neoplasm Metastases, Brain, Rectal Neoplasms
- Trial name
- HX4 SD (NCT02584400)
- Testing
- Injection with the hypoxia tracer [18F]HX4,
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- Maastricht Radiation Oncology
Metastatic Colorectal Cancer
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
This study intends to optimize a fluorouracil/irinotecan chemotherapy regimen by the identification of individual thymidylate synthase (TS) and UDP-glucuronosyltransferase 1 (UGT1A1) polymorphisms before the first administration.
- Trial name
- NCT00138060
- Testing
- irinotecan, 5 fluorouracil
- Where
- 6 sites in France
- Volunteers
- 71 people
- Sponsor
- Institut de Recherche Clinique sur les Cancers et le Sang
Colorectal Neoplasms, Trifluridine and Tipiracil
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care…
- Conditions
- Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
- Trial name
- ALTAIR (NCT04457297)
- Testing
- trifluridine and tipiracil
- Where
- 39 sites in Japan, Taiwan
- Volunteers
- 243 people
- Sponsor
- National Cancer Center Hospital East
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Elderly Metastatic Colorectal Cancer Patients
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer
Oxaliplatin-based doublets plus bevacizumab are standard first-line therapy options for patients (pts) with metastatic colorectal cancer (mCRC).
- Trial name
- COBRA (NCT03451370)
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.